TELA
TELA Bio·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About TELA
Tela Bio, Inc.
A commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions
Healthcare Equipment and Supplies
04/17/2012
11/08/2019
NASDAQ Stock Exchange
209
12-31
Common stock
1 Great Valley Parkway, Suite 24, Malvern, Pennsylvania 19355
--
TELA Bio, Inc., was incorporated in Delaware on April 17, 2012. The company is a commercial stage medical technology company focused on providing innovative soft tissue reconstruction solutions that optimize clinical outcomes by prioritizing preservation and restoration of the patient's own anatomy. The company's growing product portfolio is designed to capitalize on patients' natural healing responses while minimizing long-term exposure to permanent synthetic materials. The company is committed to providing advanced technologies with a strong economic value proposition to assist surgeons and institutions in delivering next-generation soft tissue repair solutions to more patients around the world. Er patient care.
Earnings Call
Q1/2025
Estimate EPS-0.21
Actual EPS-0.25
Estimate Revenue17.35M
Actual Revenue18.50M
TELA Bio's 2025 Q1 Earnings Call: Navigating Contradictions in Tariff Impact, Revenue Growth, and Sales Force Dynamics
May 19,2025 06:01
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.19
Actual EPS-0.22
Estimate Revenue20.67M
Actual Revenue20.20M
Contradictions Unveiled: TELA Bio's Q2 2025 Earnings Call Highlights Shifts in Sales Strategy, Product Growth, and Pricing Positioning
Aug 11,2025 07:32
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
TELA has released its 2025 Q3 earnings. EPS was reported at -0.19, versus the expected -0.2, beating expectations. The chart below visualizes how TELA has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
TELA has released its 2025 Q3 earnings report, with revenue of 20.69M, reflecting a YoY change of 9.14%, and net profit of -8.60M, showing a YoY change of 17.06%. The Sankey diagram below clearly presents TELA's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
